Imagine a broken bone that just won't knit back together, usually requiring a second painful surgery to steal bone from another part of the body. This technology uses a special protein mixed with the patient's own blood and a ceramic base to create a custom 'bone-growing' plug. It acts like a biological spark plug that tells the body to regrow bone exactly where it is needed without needing extra surgery.
Bone fracture nonunions cause long-term pain and high healthcare costs, yet no approved biological drug exists for this condition. Current treatments require invasive bone harvesting from the patient's own body, leading to additional complications and morbidity.
A biological drug called OSTEOGROW-C, consisting of rhBMP6 protein, an autologous blood coagulum, and tricalcium phosphate ceramics.
If you are a surgical clinic dealing with patients whose fractures fail to heal—this project developed OSTEOGROW-C that eliminates the need for painful bone harvesting. It allows surgeons to create a personalized implant in the operating room using the patient's own blood.
If you are a biotech firm dealing with the lack of approved biological drugs for bone nonunions—this project developed a production process for recombinant human bone morphogenetic protein 6 (rhBMP6). This provides a scalable way to produce the active biological component for bone regeneration.
If you are a hospital network dealing with high costs and long recovery times for 180,000 annual long bone nonunions in Europe—this project developed a therapy that reduces complications and shortens recovery. This lowers the long-term healthcare burden and societal costs.
Based on available project data, specific pricing for OSTEOGROW-C is not provided, though it is noted to lower long-term healthcare and societal costs by reducing the need for invasive bone harvesting.
The project focuses on the optimization and scaling of the production process for the active biological component, recombinant human bone morphogenetic protein 6 (rhBMP6), to ensure consistent quality.
The OSTEOGROW-C product is described as globally patented, indicating that the intellectual property is secured by Genera Research.
The project aims to complete late-stage clinical development and regulatory preparation to become the first approved biological treatment for bone fracture nonunions in Europe and internationally.
The project period is from 2025-01-01 to 2026-12-31, focusing on manufacturing readiness and regulatory preparation for launch in the EU and US.
The project is led by a single SME, Genera Istraživanja, based in Croatia. With a 100% industry ratio and a total EU contribution of EUR 2,499,999, the structure is lean and focused entirely on commercialization rather than academic research, which typically accelerates the path to market.
Contact Genera Istraživanja Drustvo s Ogranicenom Odgovornoscu za Proizvodnju Biotechnoloskih Proizvoda in Croatia
Contact us to explore licensing opportunities for OSTEOGROW-C or to partner on clinical trial scaling.
